EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial stability, with cash funding operations into Q4 2027, and promising developments in the DURAVYU trials, targeting a $10 billion market. The Q&A reveals positive sentiment about DURAVYU's multi-mechanism profile and commercial readiness, despite some unclear responses. The company's strategic positioning and promising trial outcomes suggest a positive stock price reaction, although the lack of a market cap limits the prediction's precision.
Key Financial Performance
Total net revenue for Q4 2025 $0.6 million, a decrease from $11.6 million in Q4 2024. The decrease was primarily driven by the recognition of remaining deferred revenue related to the company's agreement for the license of YUTIQ product rights in the second quarter of 2023.
Operating expenses for Q4 2025 $71 million, an increase from $57 million in Q4 2024. This increase was primarily driven by the ongoing Phase III trials for DURAVYU in wet AMD and DME.
Net loss for Q4 2025 $68 million or $0.81 per share, compared to a net loss of $41 million or $0.64 per share in Q4 2024. The increase in net loss was due to higher operating expenses.
Total net revenue for full year 2025 $31 million, a decrease from $43 million in 2024. The decrease was primarily driven by the recognition of remaining deferred revenue related to the company's agreement for the license of YUTIQ product rights in the second quarter of 2023.
Operating expenses for full year 2025 $275 million, an increase from $189 million in 2024. This increase was primarily driven by the ongoing Phase III trials for DURAVYU in wet AMD and DME.
Net loss for full year 2025 $232 million or $3.17 per share, compared to a net loss of $131 million or $2.32 per share in 2024. The increase in net loss was due to higher operating expenses.
Cash and investments as of December 31, 2025 $306 million, a decrease from $371 million as of December 31, 2024. The decrease was due to funding ongoing operations and clinical trials.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DURAVYU development: DURAVYU is being advanced as a treatment for wet AMD and DME. Phase III trials for DME have begun, and top-line data for wet AMD is expected in mid-2026. DURAVYU has shown durable efficacy, improved vision, and a favorable safety profile in Phase II trials.
DURAVYU's unique profile: DURAVYU offers a differentiated profile with a multi-MOA targeting VEGF, PDGF, and IL-6, potentially enabling improved long-term outcomes with fewer injections. It is positioned for every 6-month dosing via intravitreal injection.
Market potential for DURAVYU: The global market for wet AMD and DME is currently $10 billion and growing. DURAVYU is positioned to address the largest retinal disease markets with its unique MOA and clinical benefits.
Manufacturing facility expansion: EyePoint expanded operations at its 41,000 square foot cGMP manufacturing facility in Northbridge, Massachusetts, which supports both clinical and commercial supply.
Financial position: EyePoint ended 2025 with $306 million in cash and investments, expected to fund operations into Q4 2027. Operating expenses increased due to ongoing Phase III trials.
Commercial readiness: EyePoint appointed Michael Campbell as Chief Commercial Officer to prepare for DURAVYU's U.S. launch. The company is also preparing for regulatory submissions and pre-approval inspections.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Total net revenue for the quarter ended December 31, 2025, was $0.6 million, a significant decrease from $11.6 million in the same quarter of 2024. This decline was primarily due to the recognition of remaining deferred revenue related to the company's agreement for the license of YUTIQ product rights in 2023.
Increased Operating Expenses: Operating expenses for the quarter ended December 31, 2025, totaled $71 million, up from $57 million in the prior year period. This increase was driven by ongoing Phase III trials for DURAVYU in wet AMD and DME, which could strain financial resources.
Net Loss: The company reported a net loss of $68 million for the quarter ended December 31, 2025, compared to a net loss of $41 million in the prior year period. For the full year, the net loss was $232 million, up from $131 million in 2024, indicating financial challenges.
Regulatory and Clinical Risks: The success of DURAVYU is contingent on positive Phase III trial outcomes and regulatory approvals. Any delays or negative results could significantly impact the company's strategic objectives and financial performance.
Commercial Readiness and Manufacturing: The company is preparing for regulatory submission and pre-approval inspection for DURAVYU. Any issues in these processes or delays in scaling up manufacturing at the cGMP facility could hinder the product's market launch.
Market Competition: DURAVYU aims to compete in the $10 billion global retinal disease market. The presence of established players and the need to demonstrate a compelling value proposition pose competitive challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
DURAVYU in wet AMD: Top-line data for the Phase III LUGANO trial is anticipated in mid-2026, with LUCIA data to follow closely. Regulatory filing in wet AMD is planned, assuming positive Phase III data.
DURAVYU in DME: Randomization is underway for the pivotal Phase III COMO and CAPRI trials. Top-line data is expected in the second half of 2027. The program is designed to support a compelling and relevant label.
Financial Outlook: The company has a strong cash position of $306 million, expected to fund operations into the fourth quarter of 2027, covering key milestones and NDA preparation for the wet AMD program in 2026 and fully funding the DME program.
Commercial Readiness: Preparations are underway for a U.S. launch of DURAVYU, including expansion of the cGMP manufacturing facility and pre-approval inspection readiness.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you clarify the rate of ocular adverse events (AEs) seen across the cumulative safety database with DURAVYU, particularly around vitreous floaters and cataracts? What has been the physician feedback on the safety profile?
A:The rate of cataracts in the cumulative safety database was 5.8%, while in the DAVIO 2 study, it was approximately 8% in the study arms and 9% in the Eylea control arm. For vitreous floaters, 5.2% of DURAVYU patients reported them, consistent with other studies involving eye injections. Physicians have expressed confidence in the safety and efficacy of DURAVYU, as evidenced by rapid enrollment in the wet AMD trial. No ocular or systemic serious adverse events (SAEs) have been attributed to DURAVYU in four prior trials.
Q:How is the company approaching recent FDA discussions around single-study-driven regulatory approvals? Does this change the strategy?
A:The company welcomes a faster and less expensive approval pathway but does not plan to alter its approach for wet AMD and DME, as it already has two identical Phase III trials underway for each indication. Single-trial approvals require confirmatory evidence and are more applicable to rare diseases, which wet AMD and DME are not. The company believes its current pathway is de-risked and aligned with recent regulatory trends.
Q:Will there be additional looks at masked safety in the wet AMD trials before they read out?
A:Yes, there will be ongoing internal masked reviews and independent data monitoring committee (DMC) reviews. The last DMC meeting was in November, and the next is scheduled for May. So far, the safety profile of DURAVYU has been consistent with previous Phase I and II studies.
Q:What additional biomarker work is being done to explore the activity profile of VERONA?
A:The company is conducting studies to assess the impact of JAK1 receptor inhibition and its downstream effects on IL-6. Additional data will be presented at ARVO in May. A prior evaluation of the kinome revealed vorolanib as a potent JAK1 inhibitor with no significant activity against other receptors involved in retinal disease.
Q:How prominently will DURAVYU's multi-mechanism profile beyond VEGF inhibition feature in regulatory discussions and commercial messaging?
A:The multi-mechanism profile, including IL-6 inhibition, is expected to be a key feature in regulatory discussions and commercial messaging. The company aims to demonstrate that IL-6 blockage provides a more rapid onset of visual acuity improvement, as seen in the VERONA data. Regulatory agencies may accept non-inferiority on BCVA as sufficient, but superiority on BCVA and treatment burden will also be tested. Commercially, the unique mechanism of action could position DURAVYU as a best-in-class durable treatment for wet AMD and DME.
Q:What are the key steps for commercial preparation for the potential launch of DURAVYU?
A:The company is focusing on market research, pricing research, patient access, and payer coverage to ensure a successful U.S. launch. Efforts are being made to simplify patient access and reimbursement processes. The company is also leveraging its specialty retina marketplace expertise to position DURAVYU effectively.
Q:Why are the Phase III trial designs in DME slightly different from those in wet AMD?
A:The DME trials use a different control arm dosing regimen (5 loading doses followed by every 8 weeks) as mandated by the FDA. DURAVYU is dosed on day 1 in the DME trials to replicate findings from Phase II, where early dosing showed greater improvement in BCVA and CST. This approach aims to leverage the role of IL-6 and JAK1 in DME.
Q:What is the broader clinical experience with inflammatory signals like uveitis and iritis in DURAVYU trials?
A:In 191 patients treated across four studies, there were two cases of mild iritis, both resolved with topical drops. No cases of uveitis or vitritis were reported. The overall intraocular inflammation rate was about 1%. The small molecule design of vorolanib and the matrix used in the inserts contribute to the low inflammation rates.
Q:How will the reduction in treatment burden be measured in the wet AMD studies?
A:Reduction in treatment burden will be measured after the loading doses. DURAVYU patients are expected to receive two injections in the first year, compared to five in the Eylea arm. Based on DAVIO 2 supplementation rates, a 40% reduction in treatment burden is anticipated. The study is well-powered to detect differences in treatment burden.
Q:How does the safety profile in LUGANO and LUCIA compare to DAVIO 2?
A:The safety differences in DAVIO 2 between the 2-mg and 3-mg arms were not due to vorolanib toxicity, as no maximum tolerated dose has been observed. The higher incidence of floaters in the 3-mg arm may be related to the number of inserts, but this is not a concern in the Phase III trials, which use two inserts. The overall safety profile remains strong.
Q:What are the site details for the COMO and CAPRI studies?
A:The COMO and CAPRI studies are global, with approximately 140 sites across both studies. Most sites from the wet AMD program are also participating in the DME studies, reflecting investigator confidence in the clinical program.
Q:What patient populations are KOLs considering for vorolanib, and how might step-through requirements affect adoption?
A:KOLs initially expect to use vorolanib for patients requiring frequent treatments (every 4-8 weeks). Broader adoption may occur if Phase III data show additional benefits like better vision or antifibrotic effects. Step-through requirements are not expected to be an issue, as the wet AMD study includes a 3-injection load, aligning with branded drug use.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about the mechanism of action reducing floaters. They clarified that the design of the inserts prevents free-floating drug particles but did not provide a clear link between the mechanism of action and floater reduction.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AMD DME
AMD program
Chief Commercial
Commercial Officer
DME income
DURAVYU wet
Dr Duker
Executive
EyePoint progress
III trial
IL
NDA
Officer EyePoint
Phase II
Phase III
President Chief
agreement license
control
disease market
increase Phase
label
license product
loss share
milestone
patient
profile Phase
program DURAVYU
review
right period
safety profile
track record
view
wet AMD
EYPT Transcript
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call presents a mixed outlook. Positive aspects include a 25% revenue increase and reduced net loss, but concerns arise from regulatory hurdles and strategic execution risks. The company's cash position has slightly decreased, and R&D expenses have increased, reflecting ongoing investments. Without clear guidance or significant new partnerships, the overall sentiment remains neutral, with no strong catalysts for a price movement beyond a 2% range.
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights strong financial stability, with cash funding operations into Q4 2027, and promising developments in the DURAVYU trials, targeting a $10 billion market. The Q&A reveals positive sentiment about DURAVYU's multi-mechanism profile and commercial readiness, despite some unclear responses. The company's strategic positioning and promising trial outcomes suggest a positive stock price reaction, although the lack of a market cap limits the prediction's precision.
Cardinal Health, Inc. (CAH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
EYPT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
